How Clay Siegel Is Positioning His Medical Firm In The Battle Against Cancer

Seattle has positioned itself as the undisputed cancer research center in the United States, a factor that has even prompted a sitting vice president to visit the research hubs. Some of the research facilities in the region are decades old and have come up with grand theories about the disease. But the latest entrant into the hub’s research sphere in the name Seattle Genetics under the stewardship of Dr. Clay Siegell threatens to outdo them all with a breakthrough after another.

Just recently, the Siegall had its first drug approved by both the FDA and the European market drug agencies for the treat of three types of cancerous Lymphoma. Most importantly, Siegell’s invention in the name of Adcetris is currently undergoing final tests that would make it the sole treatment for the incurable Hodgkin Lymphoma. Currently, the drug is being used to treat three types of classical lymphoma.

What makes Clay Siegall’s discovery evolutionary
Clay believes that the medical benefits of the drug extend way beyond cancer treatment. He believes that the drug can also be used to treatment of non-cancer related illnesses. In line with this claim, Clay intimated that his firm is currently testing Adcetric’s efficiency of the in the treatment of more than 70 other diseases. If it passes FDA’s approval as the primary treatment for Hodgkin Lymphoma, Adcetrics will be one of the most effective cancer treatment options available thus further igniting the already glowing hope for a cure to the cancer menace.

Clay’s entry into cancer research
The current achievements by clay in the field of medicine are just a reflection of years of hard work in the field of cancer research. After graduating with a degree in Zoology, Clay furthered his interests in research with a Ph.D. in genetics from George Washington University. He was introduced to cancer research at the National Cancer Institute where he started his career before furthering this passion with the Squibb Pharmaceutical Research Institute where he worked for over five years.

Having established a significant cancer research base with these institutions, Clay Siegall set out to build a private research facility, The Seattle Genetics that he has headed for more than a decade in the development of Adcentris and 12 other equally potent drugs that are in currently in various testing stages.

The Development of the OSI Group Into An International Business

OSI Group L.L.C is an internationally recognized company that offers a wide variety of foods and beverages. The primary industry of the food processor is based in Aurora, Illinois. The firm has been operating since 1909, and it has currently expanded to different nations and hired about 20,000 employees. The products that the company processes are vegetable products, fish, pizza, poultry, bacon, and meat patties. OSI Group is a privately owned business, and it has been named by the Forbes Magazine as the 58th enterprise in its list of the top 100 companies.

The company has also been offering top-notch services to its clients, and it was named as the 66th firm in the list of the leading 100 food and beverage processors. The success of the enterprise has been facilitated by its current CEO and chairperson, Sheldon Lavin. He is a highly experienced professional in the corporate world and the Vision World Academy honored him with the Global Visionary Award. Mr. Lavin’s career was formerly in the finance industry before OSI hired him. The input that he has added to the company has been essential in transforming it from a local food processing firm to a multinational corporation that makes profits that are worth billions of dollars. The company is currently located in about 16 countries, and it has built 60 processing factories. Apart from his role at the OSI Group, Sheldon is a trustee of the Rush University Medical Center. He is also a former employee of the National Fish & Wildlife Foundation where he served as a director.

Related: Interview with Sheldon Lavin, Chairman And CEO Of OSI Group, LLC

The company has regularly been ensuring that it develops. It has planned to expand by acquiring a top Chicago-based food processing company. The North America division’s senior executive vice president, Kevin Scott, thinks that buying the business will assist OSI to offer a wide varied of products to its clients. The firm has been working to achieve customer satisfaction, which is the primary objective of most of the top companies.

The OSI Group’s market has been expanded since it acquired Baho Food, which was formerly a Dutch-owned business. It has mainly focused on producing snacks, portable foods, and deli meats. The OSI Group will be able to penetrate Europe by using Baho Foods. The president and COO of the enterprise, David G. McDonalds, believes that the capability of OSI to process more products and brands will be increased by the Baho Foods acquisition.

The Baho Foods consist of five divisions that are based in Netherlands and Germany. These factories are Gelderland Frischwaren, Q Smart Life, Bakx Foods, Henri van de Bilt, and Vital Convenience. The company’s MD, John Balvers, and other top officers will be incorporated into the OSI Group’s executive. This was done to assist the two firms in operating and offering their services to the clients as usual. OSI Group now have a comprehensive collection of products and brands that it will provide to its customers who are based in different parts of the world.

Read more about OSI Group’s recent acquisitions and mergers here.

Clay Siegall and Seattle Genetics

Cancer is the one disease that has become a complete menace to the world of medicine. It has already surpassed HIV/AIDS, Malaria and the other diseases that were previously thought to be the top killers in the world. This is perhaps the reason why so much funding is going into the research on how to treat and possibly cure the many different types of cancer that has emerged. One company that has decided to lead the pack in getting the best treatment solutions for cancer is Seattle Genetics. The company already has a drug that is being used to deal with different types of lymphomas in the market and is currently having 12 other drugs being tried.

The company was started in 1998 by Clay Siegall. Between that time and sometime last year, Clay worked with his team through the processes of clinical tests, setbacks and re-testing till finally, the FDA accepted the improved version of their drug Adcetris. This was the turning point of his career because in the first year of being in business alone, the company has already made sales worth over quarter of a million dollars. There are also projections which suggest that the sales will increase and pass the 300 million mark by the end of the coming financial year.

The company already issued an IPO for its shares and has been trading stock on NASDAQ. In addition to trying to get the clinical trials for the remaining drugs approved, the company is thinking about hiring more employees. These high profile moves and achievements are perhaps the reason behind the visit by the deputy head of state Joe Bidden.

The marketing of the company’s drug outside the country has also been great. They have partners such as Takeda pharmaceuticals that help them sell the drug in Canada and also they are authorized to sell the drug in more than 60 other countries.

Clay Siegall
Clay has worked in biotechnology for a long time now. When he started the company, his only dream was to get a cure for the menace to mankind. Now that he is on the verge of a great discovery, he is very optimistic about the future of Seattle Genetics.

Learn more about Clay Siegall